Hengyu Medical Secures Tens of Millions in New Funding to Accelerate Development and Commercialization of Intravascular Interventional Diagnostics and Therapeutics

VCBeat learned recently,Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") has completed a financing round worth tens of millions of yuan, exclusively invested by Beiyang Haitang Fund. This is the second financing completed by Horimed within three months after receiving tens of millions of yuan from Jinhuitong Fund earlier this year, fully demonstrating the high recognition from the capital market. Haoyue Capital continuously serves as the exclusive financial advisor. This round of financing will support research and development, production, registration, and focus on accelerating the commercial promotion of products already on the market.

Horimed Technology Co., Ltd., established in 2016, focuses on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, dual-catheter systems integrated with IVUS/OCT, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology combining OCT and Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate globally based on foundational technologies, aiming to provide an integrated vascular solution based on imaging products for medical professionals and patients.

Founder of Horimed, Liu ZhiyongMr.It is noted that the precision diagnosis and treatment of vascular intervention in China has just started, and we still have a long way to go. We are very grateful for the consistent support from both new and existing shareholders. We also thank this round's financing partner, VCBeat Capital, for their strong project execution capabilities and profound and precise understanding of the industry. With the support of capital, we believe that in the future, the company will become a leader in intelligent intravascular interventional diagnosis and treatment through its solid, innovative technologies and products.

Horimed Founder Zhao ShiyongPh.D.Horimed, as a part of the precision diagnosis and treatment field in vascular intervention, will focus on technology and products in the future while also concentrating efforts on assisting clinical practices to conduct systematic training for precision diagnosis and treatment in vascular intervention. We hope to grow together with the vast number of vascular intervention doctors, enabling more and more doctors to understand, master, and commit to promoting precision diagnosis and treatment in vascular intervention. Gradually, we aim to align China with international standards in this field, ultimately benefiting more patients.

Mr. Wang Renda, Initiating Partner of Beiyang海棠 FundIt is stated that the development of intravascular imaging has greatly promoted the popularization of precision PCI procedures. Among these, IVUS and OCT can significantly improve the accuracy of PCI procedures, offering substantial benefits for patient prognosis and reducing the incidence of postoperative adverse events, which has become a consensus among industry experts. Currently, the penetration rate of IVUS and OCT in China lags significantly behind that of Europe and the U.S., but the future trend toward accelerated adoption is clear. IVUS and OCT equipment and catheters are typical cross-disciplinary technologies integrating acoustics, optics, electronics, and imaging, making talent cultivation difficult and the entry threshold high. Horimed boasts a top-tier medical-engineering team in China, with years of R&D and industrialization experience, positioning it as a leading company in IVUS and OCT in China. Currently, the company's products have been introduced in several Class III hospitals, and efforts to promote them further will continue to benefit more patients. Haitang Fund remains committed to supporting innovation and entrepreneurship among Tianjin University alumni and will continue to assist in the development of Horimed and the advancement of precision vascular intervention.

Mr. Yang Zhenjun, Managing Partner of Haoyue CapitalWe are honored to assist Horimed in completing this round of financing, which is the second financing completed by Horimed within three months, fully reflecting the high recognition from the capital market. Comprehensive and precise diagnosis and treatment are the trends in medical development. Intravascular imaging is the most powerful technique for achieving precise diagnosis in the vascular interventional field, and it has been recommended by clinical guidelines and widely recognized in high-end medical markets globally. In recent years, driven by healthcare reform and the further penetration of interventional procedures, intravascular imaging in China has experienced rapid growth and has enormous growth potential in the future. All products of Horimed have full independent intellectual property rights, with core components developed entirely in-house. The company owns platform-level technology and has the capability for large-scale production of equipment and consumables as well as cost control. Heryue Capital continues to be optimistic about the company, growing together with the enterprise, and looks forward to more high-quality products being launched soon to benefit a wide range of patients.